Get the Stockscreener App
6.595
1.66%
-0.115
Arcturus Therapeutics Holdings Inc stock is traded at $6.595, with a volume of 65,458.
It is down -1.66% in the last 24 hours and down -5.33% over the past month.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
See More
Previous Close:
$6.71
Open:
$6.75
24h Volume:
65,458
Relative Volume:
0.15
Market Cap:
$187.02M
Revenue:
$42.35M
Net Income/Loss:
$-78.67M
P/E Ratio:
-2.3419
EPS:
-2.8161
Net Cash Flow:
$-63.18M
1W Performance:
-13.18%
1M Performance:
-5.33%
6M Performance:
-14.64%
1Y Performance:
-50.42%
1-Day Range:
$6.58
$6.80
1-Week Range:
$6.565
$7.60
52-Week Range:
$5.85
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Name
Arcturus Therapeutics Holdings Inc
Sector
Industry
Phone
(858) 900-2660
Address
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
6.58 | 190.72M | 42.35M | -78.67M | -63.18M | -2.8161 |
VRTX
Vertex Pharmaceuticals Inc
|
477.14 | 121.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
657.75 | 69.52B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
868.65 | 54.49B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.29 | 39.11B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.21 | 38.46B | 4.29B | 577.22M | 641.34M | 4.2086 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | B. Riley Securities | Buy |
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Oct-24-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-23-25 | Downgrade | Citigroup | Buy → Neutral |
| Oct-22-25 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| May-28-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-28-25 | Initiated | BTIG Research | Buy |
| Aug-12-24 | Initiated | Leerink Partners | Outperform |
| Dec-13-23 | Initiated | Canaccord Genuity | Buy |
| Jul-24-23 | Initiated | William Blair | Outperform |
| May-11-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-14-22 | Resumed | Wells Fargo | Overweight |
| Nov-10-22 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Nov-03-22 | Upgrade | Citigroup | Neutral → Buy |
| Nov-02-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-10-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Jul-19-22 | Resumed | Cantor Fitzgerald | Overweight |
| May-11-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Apr-21-22 | Downgrade | Citigroup | Buy → Neutral |
| Jan-31-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Aug-12-21 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Aug-11-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-10-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jul-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Jun-21-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-17-21 | Downgrade | B. Riley Securities | Neutral → Sell |
| Jan-19-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-15-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-07-21 | Initiated | Wells Fargo | Overweight |
| Dec-29-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-29-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-29-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-23-20 | Downgrade | ROTH Capital | Buy → Sell |
| Dec-08-20 | Reiterated | B. Riley Securities | Buy |
| Dec-07-20 | Reiterated | B. Riley Securities | Buy |
| Oct-26-20 | Initiated | Barclays | Overweight |
| Oct-06-20 | Initiated | Citigroup | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-30-20 | Resumed | ROTH Capital | Buy |
| Jul-16-20 | Initiated | Raymond James | Outperform |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
| Jun-09-20 | Downgrade | WBB Securities | Buy → Hold |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Feb-07-20 | Initiated | Guggenheim | Buy |
| Feb-06-20 | Initiated | Guggenheim | Buy |
| Apr-05-19 | Initiated | H.C. Wainwright | Buy |
| Sep-20-18 | Upgrade | WBB Securities | Buy → Strong Buy |
| Jan-22-18 | Initiated | Chardan Capital Markets | Buy |
View All
Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News
Understanding Momentum Shifts in (ARCT) - Stock Traders Daily
Is Arcturus Therapeutics' ARCT-032 a Game Changer for Cystic Fibrosis - Kavout | AI
BTIG Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Price to sales forward of Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT - TradingView
If You Invested $1,000 in Arcturus Therape (ARCT) - Stock Titan
ARCTArcturus Therapeutics Holdings Inc Latest SEC Filings - Finviz
Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar? - Yahoo Finance
This Honeywell Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Sahm
Thermo Fisher, Arcturus partner on Phase III ARCT-032 cystic fibrosis trial - Yahoo Finance
ARCT Should I Buy - Intellectia AI
ARCT Initiates Coverage by Freedom Broker -- Rating Set to Buy - GuruFocus
Arcturus Picks Thermo Fisher To Support Cystic Fibrosis Therapy - Benzinga
Arcturus Therapeutics Holdings Inc. And Thermo Fisher Scientific Inc. Announce Strategic Collaboration To Advance ARCT-032 For Cystic Fibrosis - marketscreener.com
Arcturus rises on pact with Thermo Fisher for cystic fibrosis therapy - Seeking Alpha
Freedom Capital Markets Initiates Arcturus Therapeutics(ARCT.US) With Buy Rating, Announces Target Price $27 - Moomoo
Arcturus Therapeutics Announces Thermo Fisher mRNA Partnership - TipRanks
Arcturus partners with Thermo Fisher for cystic fibrosis drug By Investing.com - Investing.com Nigeria
Arcturus Therapeutics, Thermo Fisher Scientific to Collaborate on Advancing ARCT-032 in Cystic Fibrosis - marketscreener.com
Arcturus partners with Thermo Fisher for cystic fibrosis drug - Investing.com
Thermo Fisher to back Arcturus (NASDAQ: ARCT) ARCT-032 Phase 3 and manufacturing - Stock Titan
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis - Yahoo Finance
Arcturus Therapeutics Initiated at Buy by Freedom Broker - Moomoo
Price to earnings forward of Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT - TradingView
ARCT Q1 2026 Earnings: Narrower-than-expected loss as pipeline advances without revenueDividend Increase Stocks - dars.gov.et
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT - TradingView
Arcturus Therapeutics Holdings Inc. (ARCT) Investigation: Bronste - The National Law Review
Enterprise value to EBIT forward of Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT - TradingView
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Arcturus Therapeutics Holdings, Inc. Actuals & Estimates (NASDAQ:ARCT) - TradingView
ARCT Forecast — Price Target — Prediction for 2027 - TradingView
Arcturus Therapeutics Holdings Inc (ARCT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Arcturus Therapeutics Holdings Inc. Q1 2026 Earnings: EPS Beat on Reduced Losses Despite No RevenueSlow Growth Warning - Bölüm Sonu Canavarı
Discipline and Rules-Based Execution in ARCT Response - Stock Traders Daily
ARCT SEC FilingsArcturus Therape 10-K, 10-Q, 8-K Forms - Stock Titan
Arcturus Therapeutics Holdings Inc (ARCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ARCT Q1 2026 Earnings: Narrower-than-expected loss highlights clinical momentumMid-Term Outlook - newsline.com
Arcturus Therapeutics Holdings Inc (ARCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arcturus Therapeutics Holdings Inc - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Institutional Confidence - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Arcturus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director HOLMES EDWARD W - Moomoo
Arcturus (NASDAQ: ARCT) director receives 15,000 stock options as 2026 grant - Stock Titan
Director Peter Farrell receives 15,000 Arcturus (NASDAQ: ARCT) stock options - Stock Titan
Arcturus Therapeutics Holdings Inc Stock (ARCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.89%
3.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):